Trial Profile
A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Evacetrapib (Primary) ; Atorvastatin; Ezetimibe
- Indications Hypercholesterolaemia
- Focus Registrational; Therapeutic Use
- Sponsors Eli Lilly and Company
- 03 Aug 2017 Primary endpoint (Percent Change from Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification, Evacetrapib vs Ezetimibe) has not been met as per results published in the Circulation Journal
- 03 Aug 2017 Primary endpoint (Percent Change from Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification, Evacetrapib vs placebo) has been met as per results published in the Circulation Journal.
- 03 Aug 2017 Results published in the Circulation Journal